IVERIC bio Stock Doubled and Continues to Outperform

IVERIC bio Stock Outperforms
IVERIC bio (ISEE) has good news its stock is responding to. A randomized, controlled Phase 2b clinical trial data seem to confirm that the IVERIC bio product Zimura® (avacincaptad pegol), a complement factor C5 inhibitor, has met its prespecified primary endpoint in reducing the rate of geographic atrophy (GA) growth in . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.